Abstract: Objective To compare the effects of low-dose Xuezhikang with that of Pravastatin for long-term therapy on Chinese patients with dyslipidemia. Methods One hundred and ninety-five cases from six hospitals in Beijing were studied by being randomly divided into two groups and given Xuezhikang 2 capsules QN and Pravastatin 5 mg QN respectively for 6 months. The levels of TC, TG, LDL-C and HDL-C in pre- and post-treatment for each group were analyzed. The differences between the two groups were compared using ANOVA. The efficacy-rates for lowering TC, TG and increasing HDL-C of each group were calculated according to "The Guidline to Clinical Drug Research" and the differences between the two groups were compared with X² test. Results Comparing with pre-treatment the TC decreased 16% and 17%, TG decreased 13% and 15%, LDL-C decreased 23% and 21%, HDL-C increased 2% and 10% after administering for 6 months in Xuezhikang and Pravastatin groups respectively. Both of the drugs could decrease LDL/HDL effectively as well. The decreases of TC, TG, LDL-C, and LDL/HDL were statistically significant in both groups comparing with pre-treatment, however, no significant differences were found between the two groups. But there was significant difference in the increases of HDL-C between two groups. The efficacy-rates of Xuezhikang and Pravastatin were 54.6% and 68.4% for TC, 49.1% and 53.9% for HDL-C, 46.2% and 40.8% for TG respectively. There were no significant differences between the two groups. No severe side effects were observed in the two groups. Conclusion Low-dose statin drugs (such as Xuezhikang and Pravastatin) administrated in relatively long-term are effective and safe for Chinese patients with dyslipidemia.

Key words: Xuezhikang/therapeutical, Xuezhikang/therapeutical, Pravastatin/therapeutical usage, Pravastatin/therapeutical usage, Hyperlipidemia, Hyperlipidemia